FDA and EMA get comfortable in joint inspections; GSK, Pfizer provide discounted vax to GAVI;

> The FDA and the European Medicines Agency continue to cozy up, moving from confidence-building in their joint GMP inspections to reliance upon each other. Story

> GlaxoSmithKline ($GSK) and Pfizer ($PFE) say they will provide 180 million doses of discounted pneumococcal vaccine for use by the Global Alliance for Vaccines and Immunization. Story

> Covidien ($COV) says it plans to spin off its $2 billion pharmaceuticals business, creating a public company. Article

> DSM Sinochem Pharmaceuticals will build a production facility for semi-synthetic cephalosporins in Zibo, China. Story

> Pfizer ($PFE) has put three real estate lots--the last of its presence in Brooklyn--on the market. Item

> Contract service provider Advanced BioScience Labs has hired industry vet Claire Zhang to lead its downstream bioprocessing group. Item

> Lonza has expanded its early-phase, small-molecule manufacturing capacity in Nansha, China. Announcement

> Tom Flachmeyer has joined Prolong Pharmaceuticals to head the engineering and facilities planning function for it oxygen therapeutic product, Sanguinate. Story

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.